Novartis Pharmaceuticals Corporation v. Lupin Inc. et al

Docket(#9) WAIVER OF SERVICE returned executed by Novartis Pharmaceuticals Corporation: For Lupin Pharmaceuticals, Inc. waiver sent on 9/25/2024, answer due 11/25/2024. (Silver, Daniel) (Entered: 10/02/2024)

Docket(#8) WAIVER OF SERVICE returned executed by Novartis Pharmaceuticals Corporation: For Lupin Limited waiver sent on 9/25/2024, answer due 11/25/2024. (Silver, Daniel) (Entered: 10/02/2024)

Docket(#7) WAIVER OF SERVICE returned executed by Novartis Pharmaceuticals Corporation: For Lupin Inc. waiver sent on 9/25/2024, answer due 11/25/2024. (Silver, Daniel) (Entered: 10/02/2024)

Docket(#6) WAIVER OF SERVICE returned executed by Novartis Pharmaceuticals Corporation: For Lupin Atlantis Holdings, S.A. waiver sent on 9/25/2024, answer due 11/25/2024. (Silver, Daniel) (Entered: 10/02/2024)

DocketRemark: The MDL panel has been advised. (mpb) (Entered: 09/25/2024)

DocketCase Assigned to Judge Richard G. Andrews. Please include the initials of the Judge (RGA) after the case number on all documents filed. (rjb) (Entered: 09/25/2024)

DocketNo Summons Issued. (mpb) (Entered: 09/18/2024)

Docket(#5) Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Novartis AG for Novartis Pharmaceuticals Corporation filed by Novartis Pharmaceuticals Corporation. (mpb) (Entered: 09/18/2024)

Docket(#4) Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,101,659; 11,096,918. (mpb) (Entered: 09/18/2024)

Docket(#3) Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 8/6/2024. Date of Expiration of Patent: See Attached.Thirty Month Stay Deadline: 2/6/2027. (mpb) (Entered: 09/18/2024)

Docket(#2) Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (mpb) (Entered: 09/18/2024)

Docket(#1) COMPLAINT against Lupin Atlantis Holdings, S.A., Lupin Inc., Lupin Limited, and Lupin Pharmaceuticals, Inc. (Filing fee $ 405, receipt number ADEDC-4501085) - filed by Novartis Pharmaceuticals Corporation. (Attachments: #1 Exhibits A-B, #2 Civil Cover Sheet)(mpb) Modified on 9/25/2024 (nms). (Entered: 09/18/2024)